3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
7
Leucovorin
6
Irinotecan
6
Fluorouracil
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Capecitabine
4
Paclitaxel
3
Oxaliplatin
3
Ocoxin
3
Bevacizumab
3
pembrolizumab
2
entinostat
2
Sorafenib
2
Imatinib Mesylate
2
Everolimus
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
pralsetinib
1
palbociclib
1
irinotecan sucrosofate
1
halofantrine
1
guadecitabine
1
fludarabine
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Digestive System Neoplasms
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled